Your browser doesn't support javascript.
loading
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study.
Ozonoff, Al; Jayavelu, Naresh Doni; Liu, Shanshan; Melamed, Esther; Milliren, Carly E; Qi, Jingjing; Geng, Linda N; McComsey, Grace A; Cairns, Charles B; Baden, Lindsey R; Schaenman, Joanna; Shaw, Albert C; Samaha, Hady; Seyfert-Margolis, Vicki; Krammer, Florian; Rosen, Lindsey B; Steen, Hanno; Syphurs, Caitlin; Dandekar, Ravi; Shannon, Casey P; Sekaly, Rafick P; Ehrlich, Lauren I R; Corry, David B; Kheradmand, Farrah; Atkinson, Mark A; Brakenridge, Scott C; Higuita, Nelson I Agudelo; Metcalf, Jordan P; Hough, Catherine L; Messer, William B; Pulendran, Bali; Nadeau, Kari C; Davis, Mark M; Sesma, Ana Fernandez; Simon, Viviana; van Bakel, Harm; Kim-Schulze, Seunghee; Hafler, David A; Levy, Ofer; Kraft, Monica; Bime, Chris; Haddad, Elias K; Calfee, Carolyn S; Erle, David J; Langelier, Charles R; Eckalbar, Walter; Bosinger, Steven E; Peters, Bjoern; Kleinstein, Steven H; Reed, Elaine F.
Afiliação
  • Ozonoff A; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Jayavelu ND; Benaroya Research Institute, Seattle, WA, USA.
  • Liu S; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Melamed E; The University of Texas at Austin, Austin, TX, USA.
  • Milliren CE; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Qi J; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Geng LN; Stanford University, Stanford, CA, USA.
  • McComsey GA; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA.
  • Cairns CB; Drexel University/Tower Health Hospital, Philadelphia, PA, USA.
  • Baden LR; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Schaenman J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
  • Shaw AC; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.
  • Samaha H; Emory University, Atlanta, GA, USA.
  • Seyfert-Margolis V; MyOwnMed, Inc, Bethesda, MD, USA.
  • Krammer F; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Rosen LB; National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
  • Steen H; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Syphurs C; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Dandekar R; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Shannon CP; Centre for Heart Lung Innovation, Providence Research, St. Paul's Hospital, and the PROOF Centre of Excellence, Vancouver, BC, Canada.
  • Sekaly RP; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA.
  • Ehrlich LIR; The University of Texas at Austin, Austin, TX, USA.
  • Corry DB; Baylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA.
  • Kheradmand F; Baylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA.
  • Atkinson MA; University of Florida/University of South Florida, Tampa, FL, USA.
  • Brakenridge SC; University of Florida/University of South Florida, Tampa, FL, USA.
  • Higuita NIA; Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.
  • Metcalf JP; Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.
  • Hough CL; Oregon Health & Science University, Portland, OR, USA.
  • Messer WB; Oregon Health & Science University, Portland, OR, USA.
  • Pulendran B; Stanford University, Stanford, CA, USA.
  • Nadeau KC; Stanford University, Stanford, CA, USA.
  • Davis MM; Stanford University, Stanford, CA, USA.
  • Sesma AF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Simon V; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • van Bakel H; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Hafler DA; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.
  • Levy O; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Kraft M; University of Arizona, Tucson, AZ, USA.
  • Bime C; University of Arizona, Tucson, AZ, USA.
  • Haddad EK; Drexel University/Tower Health Hospital, Philadelphia, PA, USA.
  • Calfee CS; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Erle DJ; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Langelier CR; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Eckalbar W; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Bosinger SE; Emory University, Atlanta, GA, USA.
  • Peters B; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Kleinstein SH; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.
  • Reed EF; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Nat Commun ; 15(1): 216, 2024 Jan 03.
Article em En | MEDLINE | ID: mdl-38172101
ABSTRACT
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Líquidos Corporais / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Líquidos Corporais / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article